Q&A

The Global, Integrated CDMO Partner Of Choice

gettyimages-1405788998-170667a

The growing complexity of drug development and manufacturing processes is necessitating highly specialized expertise and equipment to execute these processes efficiently. As pharmaceutical companies face mounting pressure to deliver therapies to patients with speed and monetize the financial return from development candidates, it is essential for them to optimize resources. Contract development and manufacturing organizations (CDMOs) offering the right expertise, scale, and infrastructure can help to significantly reduce the overall time and complexity of drug development and manufacturing.

Pharmaceutical companies advancing their candidates to market also have to prepare to serve a global market, making it crucial to partner with a manufacturer who understands and can help them navigate the regulatory requirements and supply chain challenges of operating in various markets. The key attribute underpinning a successful CDMO relationship is ensuring your partner can cale alongside your product’s evolution. A CDMO with the ability to scale helps to optimize resources, leverage expertise, de-risk investment, and accelerate drug development timelines. Learn more as John Ross, Senior Vice President of Development and Manufacturing at PCI Pharma Services, discusses what it means to be the partner of choice in a very dynamic industry.

access the Q&A!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader